Liver Disease Therapeutics Market To Reach $40.29 Billion By 2033

Liver Disease Therapeutics Market Growth & Trends

The global liver disease therapeutics market size is expected to be valued at USD 40.29 billion by 2033, registering a CAGR of 7.9% from 2025 to 2033, according to a new report by Grand View Research, Inc. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments’ and big companies’ vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

 Request a free sample copy or view report summary: Liver Disease Therapeutics Market Report

Liver Disease Therapeutics Market Report Highlights

• The antiviral drugs segment dominated the market with the largest revenue share of 39.84% in 2024 due to the high global prevalence of chronic viral hepatitis, long treatment durations for HBV, and premium pricing for HCV DAAs.

• The hepatitis segment dominated the market with the largest revenue share of 40.44% in 2024, attributed to the widespread burden of chronic hepatitis and the clinical success of antiviral treatments, the hepatitis segment remains a major market driver.

• North America held the largest share of the liver disease therapeutics market in 2024, accounting for 39.87% of global revenue, driven by the rising prevalence of liver disease, aging populations, and breakthrough therapies.

• The liver disease therapeutics market in Asia Pacific is projected to grow at the fastest CAGR of 9.19% over the forecast period, fueled by the high prevalence of hepatitis B and C, rising NAFLD cases, and improving healthcare infrastructure.

Liver Disease Therapeutics Market Segmentation

Grand View Research has segmented the global liver disease therapeutics market on the basis of product, disease, and region:

Liver Disease Therapeutics Product Outlook (Revenue, USD Million, 2021 - 2033)

• Antiviral Drugs

• Vaccines

• Chemotherapy

• Targeted Therapy

• Immunosuppressants

• Immunoglobulins

• Corticosteroids

• Other Products

Liver Disease Therapeutics Disease Outlook (Revenue, USD Million, 2021 - 2033)

• Hepatitis

• Autoimmune Diseases

• Non-alcoholic Fatty Liver Disease (NAFLD)

• Cancer

• Genetic Disorders

• Other Diseases

Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Liver Disease Therapeutics Market

• Gilead Sciences, Inc.

• AbbVie Inc.

• Bristol-Myers Squibb Company

• F. Hoffmann-La Roche Ltd

• Takeda Pharmaceutical Company Limited.

• Johnson & Johnson Services, Inc.

• Merck & Co., Inc.

• Novartis AG

• Pfizer Inc.

• Sanofi

• GSK plc